Suggested Remit: To appraise the clinical and cost effectiveness of secukinumab within its marketing authorisation for treating plaque psoriasis in children and young people.
 
Status In progress
Process STA 2018
ID number 1669

Provisional Schedule

Committee meeting: 1 04 August 2021
Expected publication 20 October 2021

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Evidence Review Group / Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Consultees

Companies sponsors Novartis (secukinumab)
Others Department of Health and Social Care
  NHS Canterbury and Coastal CCG
  NHS England
  NHS Isle of Wight CCG
  Welsh Government
Patient carer groups Action for Sick Children
  British Skin Foundation
  Changing Faces
  Let’s Face It
  Muslim Council of Britain
  Psoriasis Association
  Psoriasis and Psoriatic Arthritis Alliance
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups British Association of Dermatologists
  British Dermatological Nursing Group
  British Geriatrics Society
  British Society for Cutaneous Allergy
  British Society for Rheumatology
  Primary Care Dermatology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics & Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies AbbVie Ltd (adalimumab)
  Amgen Ltd (adalimumab)
  Biogen Biosimilars (adalimumab, etanercept)
  Janssen-Cilag Ltd (ustekinumab)
  Mylan (adalimumab)
  Pfizer Limited (etanercept)
  Sandoz limited (adalimumab, etanercept)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Epidermo-Epidemiology Society
  Centre of Evidence-based Dermatology, University of Nottingham
  Cochrane Skin Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  Skin Treatment & Research Trust

Timeline

Key events during the development of the guidance:

Date Update
24 November 2020 Invitation to participate
09 November 2020 In progress. Topic is in progress
07 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
18 November 2019 - 16 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance